Skip to content

Amneal Pharmaceuticals

US · AMRX #1854 by market cap Listed 1970
21.12 -0.27 -1.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions increased by 29 in the most recent period (2026/Q3).
  • Total institutional ownership fell 3.0 percentage points.

Ownership vs. money flow

Aligned

Institutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
49.62% -2.97pp
Institutions
410 +29
As of
2026/Q3 vs. prior period

Holder types

Individual/Insider38.18%
Mutual Fund35.77%
Hedge Fund5.76%
VC/PE Fund3.54%
Public Company2.17%
Government Pension Fund1.06%
Insurance Company0.61%
Private Company0.48%
Other12.36%

Top holders as of 2026-08-10

Tushar Patel 17.61% · 61.34M sh
BlackRock 7.71% · 26.88M sh
Akram Mahesh 5.90% · 20.56M sh
Dipan Patel 4.85% · 16.90M sh
Chirag Patel 4.53% · 15.79M sh
Chintu Patel 3.81% · 13.26M sh
Vanguard Portfolio Management, LLC 3.55% · 12.37M sh
TPG Capital, L.P. 3.54% · 12.33M sh
Rubric Capital Management LP 2.92% · 10.17M sh
Vanguard Capital Management, LLC 2.29% · 7.99M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 35 buys · 15 sells

NameRoleStake
Tushar Patel -- 17.61%
Chirag Patel Co-Founder, Co-CEO, President & Director 4.53%
Chintu Patel Co-Chief Executive Officer 3.81%
Gautam Patel Director 0.55%
Paul Meister Independent Chairperson 0.24%
Anastasios Konidaris Chief Financial Officer 0.13%
Jeffrey George Independent Director 0.10%
Ted Nark Independent Director 0.09%
Shlomo Yanai Independent Director 0.09%
Nikita Shah Executive Vice President 0.07%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-16 J. Buchi Independent Director Other Disposition -20,445 --
2026-09-10 J. Buchi Independent Director Derivative Exercise and Retained +20,445 $14.45
2026-08-31 Andrew Boyer Executive VP and Chief Commercial Officer of Generics & Biosciences Other Disposition -80,000 --
2026-08-20 Andrew Boyer Executive VP and Chief Commercial Officer of Generics & Biosciences Other Disposition -152,426 --
2026-08-12 John Kiely Independent Director Other Disposition -10,000 --
2026-08-12 John Kiely Independent Director Open Market Disposition -50,000 $17.64
2026-08-11 Nikita Shah Executive Vice President Open Market Disposition -146,403 $17.51
2026-08-11 Jason Daly Executive Vice President Open Market Disposition -216,613 $17.40–17.70
2026-08-10 J. Buchi Independent Director Open Market Disposition -168,573 $17.18
2026-08-09 Chirag Patel Co-Founder, Co-CEO, President & Director Other Acquisition +6,381,734 --
2026-08-09 Chintu Patel Co-Chief Executive Officer Other Acquisition +6,381,734 --
2026-08-09 Tushar Patel -- Other Acquisition +12,763,469 --
2026-08-09 Gautam Patel Director Other Acquisition +283,632 --
2026-05-10 Deborah Autor Independent Director Open Market Disposition -34,819 $12.94
2026-05-06 Paul Meister Independent Chairperson Derivative Exercise and Retained +48,747 --
2026-05-06 J. Buchi Independent Director Derivative Exercise and Retained +34,819 --
2026-05-06 Ted Nark Independent Director Derivative Exercise and Retained +34,819 --
2026-05-06 Shlomo Yanai Independent Director Derivative Exercise and Retained +34,819 --
2026-05-06 Jeffrey George Independent Director Derivative Exercise and Retained +34,819 --
2026-05-06 Gautam Patel Director Derivative Exercise and Retained +34,819 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.

Amneal Pharmaceuticals discussion 0 comments

Add a comment